Investor Ideas #Podcast Corner - Chairman, CEO of Sigyn Therapeutics, Inc. (OTC: $SIGY) Discusses Treatment of Life-Threatening Conditions Induced by #Cytokine Storm Syndrome; @Sigyn_inc

 

 

 

 

Investor Ideas #Podcast Corner - Chairman, CEO of Sigyn Therapeutics, Inc. (OTC: $SIGY) Discusses Treatment of Life-Threatening Conditions Induced by #Cytokine Storm Syndrome; @Sigyn_inc

 

Point Roberts WA, Delta BC, January 25, 2021 - Investorideas.com, a global news source and leading retail investor and trader resource issues a new CEO interview for the Podcast Corner. In today’s special edition, Investor Ideas talks to Sigyn Therapeutics, Inc. (OTCMarkets: SIGY) Chairman and CEO, Jim Joyce.

 

  

Previously, Mr. Joyce was the founder and former Chairman and CEO of Aethlon Medical, Inc. (NASDAQ: AEMD)

 

Listen to today’s Podcast:  

https://www.investorideas.com/Audio/Podcasts/2021/012021SIGY-CEO-Interview.mp3

 

Read this in full at https://www.investorideas.com/news/2021/biotech/01251Podcast-SIGY-CEO-Interview.asp

 

Listen to Investor Ideas podcasts on Spotify

 

Mr. Joyce discusses Sigyn Therapeutics vision for addressing life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome stating, “Cytokine Storm Syndrome is a dis-regulated immune response that results in the overproduction of inflammatory cytokines that can induce organ failure and cause death. It can be triggered by a wide range of infectious conditions and is a leading cause of death related to severe COVID-19 infections.  It also underlies sepsis, which is the number one cause of in-hospital deaths worldwide and an annual market opportunity that exceeds $20 billion.”  Mr Joyce added that: “Cytokine Storm Syndrome can also be triggered by non-infectious disease conditions such as an adverse response to drug therapies including emerging cancer immunotherapies.”

 

Mr. Joyce further discussed how the limitations of single-target drugs have created an increased interest in extracorporeal blood purification technologies that can address a broad-spectrum of inflammatory targets, whereas anti-Cytokine drug agents are limited to a single Cytokine target.

 

Continued: “We really see two pioneering devices and they happen to be associated with public companies. One is the CytoSorb device from CytoSorbents Corporation (NASDAQ: CTSO) which has a market value of approximately $400 million. This device is designed to reduce the presence of a broad-spectrum of inflammatory cytokines from circulation.”

 

Continued: “The other device is the Toraymyxin Device which is a product of Toray Industries, Inc. (3402.T) based in Japan.  This is one of about several products from Toray that drives a market value of about $10 billion. The Toraymyxin product eliminates circulating endotoxins, which is a potent activator of the cytokine storm.”

 

Continued: “However, it does not address inflammatory Cytokines.  Inversely, CytoSorb addresses inflammatory Cytokines but doesn't address endotoxin. So that's something we took into great consideration when we designed Sigyn Therapy to simultaneously address inflammatory Cytokines, endotoxin and much larger CytoVesicles that transport inflammatory Cytokine cargos throughout the circulatory system (OTCMarkets: SIGY).”

 

Sigyn Therapeutics is a development-stage therapeutic technology company headquartered in San Diego, California, USA. Their focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome. Their mission is to save lives.

 

Sigyn Therapy™ is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.

 

Joyce also discusses his previous leadership role at Aethlon Medical, Inc. (NASDAQ: AEMD) where he oversaw the development of the Hemopurifier to treat life-threatening viral infections and address tumor-derived exosomes in cancer patients as a great experience prior to founding Sigyn Therapeutics, Inc.

 

To learn more, visit www.SigynTherapeutics.com  or www.SigynTherapy.com

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

The Investorideas.com podcasts are also available on iTunes,  Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio and Google Play Music.

Visit the Podcast page at Investorideas.com: https://www.investorideas.com/Audio/

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood , Acorn, Stash  and others.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Disclosure: the distribution of this podcast was paid for by Sigyn Therapeutics (2000) Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800-665-0411

 

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

 

#AI #Health #Stock News: GBT (OTCPINK: $GTCH) Researching AI based, #Robotics #Technology for the Medical Field

  

 

#AI #Health #Stock News: GBT (OTCPINK: $GTCH) Researching AI based, #Robotics #Technology for the Medical Field

 

San Diego, CA, January 21, 2021 – (Investorideas.com Newswire) GBT Technologies Inc. (OTCPINK: GTCH) ("GBT”, or the “Company”) is researching AI based, robotics technology for the medial field. Due to the expected growth in the global medical robotics industry through 2023*, a wide range of robots are being developed to serve in a variety of roles within the medical environment.  Probably one of the most famous medicals robot is the da Vinci Surgical System**, that was approved by the FDA in 2000. This system is designed to perform minimally invasive surgeries and is controlled by a surgeon from a console.

 

Read this news, featuring GTCH in full at https://www.investorideas.com/CO/GOPH/news/2021/01211Robotics-Technology-Medical-Field.asp

 

GBT is commencing new research that is targeting medical application robotics, empowered by its AI system. In this research, the Company will focus on the innovation and technological advancements that is offered by AI to enable medical robots achieving higher standards. Using AI technology, robots can perform minimally invasive procedures with high accuracy and precision. For example, performing laser incisions on soft tissue, especially for microsurgeries. Using expert system guidance, one of the research goals, is to perform robotic based laser incisions simulation based on surgeon high level commands where an AI engine controls a high precision laser beam to achieve a desired incision shape, length, and depth. Another planned topic to be researched is robotic assistance for biopsies where under robotic guidance a surgeon can performs a biopsy based on 3D imaging of the area. The Company plans to develop simulated procedures and flows to be tested for further medical purposes.

 

“The field of robotics is under constant development in many areas of our daily lives. One of the popular fields that robotics researchers invest major efforts, is the medical arena. Today’s robots can take patient’s vitals, assist with prosthetics, perform an endoscopy (looking inside the human body typically via Camera) and complex surgeries. As the demand for less invasive, less painful, high precision procedures is rapidly growing, we will be evaluating our AI system for these types of procedure. Our goal is to utilize a high precision mechanical arm based robotic system in simulated medical procedures supervised by an expert system. The plan is to investigate into soft tissues ultra-fine laser incisions, 3D imaging, and intelligent navigation to organs sites of interest. Our goal is to develop low and high level programs to command robotic mechanism for various physicians assisting tasks. Our research will involve full robotic automation, a physician assistant, and a combination of both. The research is planned to be on-going and we plan to produce technical papers with conclusions and results. Based on our results, we will then seek commercial partners in this domain,” said Danny Rittman the Company’s CTO.

 

 *Source: Medical Robotics Market To Reach Over US$ 20 Bn By 2023 - Credence Research

**   Source:  da Vinci Surgical System - Wikipedia

 

About Us

GBT Technologies, Inc. (OTC PINK: GTCH) (“GBT”) (http://gbtti.com) is a development stage company which considers itself a native of Internet of Things (IoT), Artificial Intelligence (AI) and Enabled Mobile Technology Platforms used to increase IC performance. GBT has assembled a team with extensive technology expertise and is building an intellectual property portfolio consisting of many patents. GBT’s mission, to license the technology and IP to synergetic partners in the areas of hardware and software. Once commercialized, it is GBT’s goal to have a suite of products including smart microchips, AI, encryption, Blockchain, IC design, mobile security applications, database management protocols, with tracking and supporting cloud software (without the need for GPS). GBT envisions this system as a creation of a global mesh network using advanced nodes and super performing new generation IC technology. The core of the system will be its advanced microchip technology; technology that can be installed in any mobile or fixed device worldwide. GBT’s vision is to produce this system as a low cost, secure, private-mesh-network between any and all enabled devices. Thus, providing shared processing, advanced mobile database management and sharing while using these enhanced mobile features as an alternative to traditional carrier services.

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements".  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products.  The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

 

Contact:

Dr. Danny Rittman, CTO
press@gopherprotocol.com

 

GBT Technologies Inc. (OTCQB:GTCH) is a featured tech stock on

Investorideas.com

 

More info on GTCH at Investorideas.com Visit: https://www.investorideas.com/CO/GOPH/

 

Get News Alerts on GBT Technologies Inc GTCH

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GTCH is a PR, social media and publishing client and compensates Investorideas.com https://www.investorideas.com/About/News/Clientspecifics.asp

Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

  Get more tech stocks investor ideas- news, articles, podcasts and stock directories

 

 

 

 

 

 

 

New Biotech, Tech and Agriculture Stocks to Watch at Investor Ideas – (NASDAQ: $KNTE) (NASDAQ: $SGTX) (NASDAQ: $PUBM) (NASDAQ: $HYFM)

 New Biotech, Tech and Agriculture Stocks to Watch at Investor Ideas – (NASDAQ: $KNTE) (NASDAQ: $SGTX) (NASDAQ: $PUBM) (NASDAQ: $HYFM)

 

Point Roberts WA, Delta BC, January 15, 2021 – (Investorideas.com Newswire) Investorideas.com, a global news source and leading retail investor and trader resource, announces its weekly roundup of stocks to watch in Biotech, Tech and Agriculture. Today’s stocks have been added to our list of free stock directories in each sector.

 

Read this in full at https://www.investorideas.com/news/2021/main/01151Stocks.asp

 

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

 

All new companies are December IPO’s.  The biotech companies include life sciences and biopharmaceutical companies. 

 

The latest tech companies are involved in ecommerce, cloud, fintech and AI and include cross-overs into the China-Asia Nasdaq IPO sector.

 

The newest agriculture company is involved in hydroponics.

 

New Stocks added to Biotech Stocks Directory:

Kinnate Biopharma Inc.(NasdaqGS: KNTE) is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Kinnate’s mission is to expand the reach of targeted therapeutics by developing products for underserved populations. Kinnate utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which it refers to as the Kinnate Discovery Engine, to develop targeted therapies. Based in San Francisco and San Diego, California, the Kinnate team is composed of drug discovery experts supported by a distinguished group of scientific advisors.

 

Sigilon Therapeutics, Inc. (NasdaqGS:SGTX)  seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal storage disorders. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

 

Silverback Therapeutics, Inc. (NasdaqGM:SBTX) is a clinical-stage biopharmaceutical company leveraging our proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Our platform enables us to strategically pair linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed to specific disease sites. Initially, we are creating a new class of targeted immuno-oncology agents that direct a myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing.

 

Pharming Group N.V. (NasdaqGS:PHAR) . is a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs.

 

BioAtla, Inc. (NasdaqGS:BCAB) is a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.

 

Scopus Biopharma Inc. (NasdaqGS:SCPS) is a biopharmaceutical company developing transformational therapeutics capitalizing on groundbreaking scientific and medical discoveries from leading research and academic institutions. The company's lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. The company is also developing additional new chemical entities to treat other serious diseases with significant unmet medical needs, including systemic sclerosis.

 

Certara, Inc. (NasdaqGS: CERT) accelerates medicines to patients using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,600 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 60 countries.

 

Seer, Inc. (NasdasqGS:SEER) is a life sciences company focused on enabling exceptional scientific outcomes by commercializing transformative products that will drive breakthrough ideas by unlocking the deep, unbiased biological information that can make them a reality. Seer is developing its Proteograph™, which is an integrated solution consisting of consumables, automation instrumentation and proprietary software that performs deep, unbiased proteomics analysis at scale in a matter of hours. Seer designed the Proteograph to be efficient and easy-to-use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution broadly available to life sciences researchers

 

AbCellera Biologics Inc. (NasdasqGS:ABCL) is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development.

                                       

4D Molecular Therapeutics Inc. (NasdaqGS:FDMT) is a clinical-stage gene therapy company pioneering the development of product candidates using targeted and evolved AAV vectors. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP, 4D-110 is in a Phase 1 clinical trial for choroideremia and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease.

                   

                   

Vivos Therapeutics, Inc. (NasdaqCM:VVOS) is a medical technology company focused on the development and commercialization of a highly differentiated technology offering a clinically effective non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). We believe our products and technology represent a significant improvement in the treatment of mild-to-moderate OSA versus other treatments such as continuous positive airway pressure (or CPAP).

 

New Stocks added to Technology Stocks Directory:

PubMatic, Inc. (NasdaqGS: PUBM) delivers superior revenue to publishers by being an SSP of choice for agencies and advertisers. PubMatic’s cloud infrastructure platform for digital advertising empowers app developers and publishers to increase monetization while enabling media buyers to drive return on investment by reaching and engaging their target audiences in brand-safe, premium environments across ad formats and devices. Since 2006, PubMatic has been expanding its owned and operated global infrastructure and continues to cultivate programmatic innovation. Headquartered in Redwood City, California, PubMatic operates 14 offices and eight data centers worldwide.

 

ContextLogic Inc. (NasdaqGS:WISH) Founded in 2010 and headquartered in San Francisco, Wish is one of the largest and fastest growing global ecommerce platforms, connecting more than 100 million monthly active users in over 100 countries to over 500,000 merchants around the world. Wish combines technology and data science capabilities and an innovative discovery-based mobile shopping experience to create a highly-visual, entertaining, and personalized shopping experience for its users. This combination has allowed Wish to become the most downloaded global shopping app for each of the last three years.

 

Wunong Net Technology Co Ltd (NasdasqGS:WNW) operates as an e-commerce company retailing food products. The Company sells green food, organic food, heritage food products, pollution-free products, and more. Food safety, product quality and sustainability are the company's core values. Wunong is committed to providing their customers with safe, high-quality, nutritious, tasty and non-genetically modified food products through their portfolio of trusted and well-known suppliers.

 

Oriental Culture Holding LTD (NasdaqGS:OCG) is an online provider of collectibles and artwork e-commerce services, which allow collectors, artists, art dealers and owners to access an art trading market with a wider range of collectibles and artwork investors. Through its subsidiaries in Hong Kong , the Company provides trading facilitation for individual and institutional customers of all kinds of collectibles, artworks and certain commodities on its online platforms, as well as online and offline integrated marketing, storage and technical maintenance service to customers in China

 

Upstart Holdings, Inc. (NasdaqGS:UPST) is a leading AI lending platform partnering with banks to expand access to affordable credit.

 

17 Education & Technology Group Inc. (NasdaqGS:YS) is a leading education technology company in China with an “in-school + after-school” integrated model. The Company provides a smart in-school classroom solution that delivers data-driven teaching, learning and assessment products to teachers, students and parents, covering over 70,000 K-12 schools in the first half of 2020. Leveraging the Company’s in-school leadership, 17EdTech offers online K-12 large-class after-school tutoring services that complement students’ in-school learning. Powered by its integrated model and technology, 17EdTech’s online K-12 large-class after-school tutoring courses stand out in terms of its unique approach to personalization, realized through a data-driven understanding of individual students’ in-school performance, as well as district-level localized insights.

 

New Stocks added to Agriculture Stocks Directory:

HYDROFARM HOLDINGS GROUP, INC. (NasdaqGS:HYFM) is a leading independent distributor and manufacturer of hydroponics equipment and supplies for controlled environment agriculture, including high-intensity grow lights, climate control solutions, and growing media, as well as a broad portfolio of innovative and proprietary branded products. For over 40 years, Hydrofarm has helped growers make growing easier and more productive. The Company’s mission is to empower growers, farmers and cultivators with products that enable greater quality, efficiency, consistency and speed in their grow projects.

 

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news and press releases, research and our own original financial content. We were one of the first retail investor sites to cover renewable energy and cleantech stocks at investorideas.com and our domain Renewableenergystocks.com. We were also one of the most well- known and cited defense stock sites, featuring our domain Homelanddefensestocks.com at its peak.

We follow the money for investors as sector sentiment shifts and technology disrupts. Our mission is to provide investor ideas with breaking news, resources, industry articles and interviews with leading experts.      

 

Learn about investing in stocks and sector trends with our news alerts, articles,  podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining and the AI Eye.

 

Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.  

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android  

 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411